Regulatory approval

Published by the Health Service Executive. Withdrawn

Treatment of oestrogen receptor positive advanced breast cancer in pre- or post-menopausal women.

This is written in the approval document.

Reimbursement

N/A

Citation

Tamoxifen Monotherapy, 2026, version number 6, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6357/253_v5_Tamoxifen_Monotherapy.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2014-11-01	Health Service Executive	Indication approved for reimbursement.